研究者詳細 - 井川　和代

論文 - 井川　和代

分割表示 48 件中 1 - 20 件目／全件表示 >>

The Early Response After Radiation Therapy on Three-Dimensional Oral Cancer Model Using Patient-Derived Cancer-Associated Fibroblasts

Izumi Yamamoto, Kazuyo Igawa, Natsuko Kondo, Yoshinori Sakurai, Atsushi Fujimura, Kiyofumi Takabatake, Peng Huang, Hiroyuki Michiue, Soichiro Ibaragi, Kenji Izumi

International Journal of Translational Medicine 5 ( 1 ) 12 - 12 2025年3月

担当区分：責任著者掲載種別：研究論文（学術雑誌）出版者・発行元：MDPI AG

Background/Objectives: Cancer-associated fibroblasts (CAFs), which are an important component of the tumor microenvironment, have been reported to have an adverse effect on conventional radiotherapy. This study aims to elucidate the effects of CAFs in boron neutron capture therapy (BNCT) using a three-dimensional (3D) oral cancer model. Methods: Three-dimensional cancer models were fabricated using patient-derived CAFs or patient-derived normal oral fibroblasts (NOFs) and a human oral squamous cell carcinoma cell line. Each 3D cancer model was performed with either a conventional X-ray treatment or BNCT and additionally analyzed histomorphologically. Results: The 3D oral cancer-CAFs model demonstrated a greater depth of cancer cell invasion than the 3D oral cancer-NOFs model. Radiation therapy for the 3D oral cancer models indicated a trend for decreasing cancer cell invasion and cell number with dose dependence in both X-ray and BNCT. In comparison with X-rays, BNCT showed a consistent increase in the number of NOFs and a significant reduction in the number of CAFs. Conclusions: BNCT for the 3D oral cancer model was shown to be effective against cancer cells and CAFs but not against NOFs, indicating its usefulness as a minimally invasive treatment for advanced cancer. Furthermore, it is indicated that the 3D oral cancer-CAFs model is a valuable tool to evaluate cancer treatment and research, particularly in high-grade malignant tumors with invasion.

DOI： 10.3390/ijtm5010012

Development and Characterization of a Three-Dimensional Organotypic In Vitro Oral Cancer Model with Four Co-Cultured Cell Types, Including Patient-Derived Cancer-Associated Fibroblasts. 国際誌

Yuka Aizawa, Kenta Haga, Nagako Yoshiba, Witsanu Yortchan, Sho Takada, Rintaro Tanaka, Eriko Naito, Tatsuya Abé, Satoshi Maruyama, Manabu Yamazaki, Jun-Ichi Tanuma, Kazuyo Igawa, Kei Tomihara, Shinsaku Togo, Kenji Izumi

Biomedicines 12 ( 10 ) 2024年10月

記述言語：英語掲載種別：研究論文（学術雑誌）

Background/Objectives: Cancer organoids have emerged as a valuable tool of three-dimensional (3D) cell cultures to investigate tumor heterogeneity and predict tumor behavior and treatment response. We developed a 3D organotypic culture model of oral squamous cell carcinoma (OSCC) to recapitulate the tumor-stromal interface by co-culturing four cell types, including patient-derived cancer-associated fibroblasts (PD-CAFs). Methods: A stainless-steel ring was used twice to create the horizontal positioning of the cancer stroma (adjoining normal oral mucosa connective tissue) and the OSCC layer (surrounding normal oral mucosa epithelial layer). Combined with a structured bi-layered model of the epithelial component and the underlying stroma, this protocol enabled us to construct four distinct portions mimicking the oral cancer tissue arising in the oral mucosa. Results: In this model, α-smooth muscle actin-positive PD-CAFs were localized in close proximity to the OSCC layer, suggesting a crosstalk between them. Furthermore, a linear laminin-γ2 expression was lacking at the interface between the OSCC layer and the underlying stromal layer, indicating the loss of the basement membrane-like structure. Conclusions: Since the specific 3D architecture and polarity mimicking oral cancer in vivo provides a more accurate milieu of the tumor microenvironment (TME), it could be crucial in elucidating oral cancer TME.

DOI： 10.3390/biomedicines12102373

Overcoming immunotherapy resistance and inducing abscopal effects with boron neutron <scp>immunotherapy</scp> (B‐<scp>NIT</scp>) 査読

Takuya Fujimoto, Osamu Yamasaki, Noriyuki Kanehira, Hirokazu Matsushita, Yoshinori Sakurai, Naoya Kenmotsu, Ryo Mizuta, Natsuko Kondo, Takushi Takata, Mizuki Kitamatsu, Kazuyo Igawa, Atsushi Fujimura, Yoshihiro Otani, Makoto Shirakawa, Kunitoshi Shigeyasu, Fuminori Teraishi, Yosuke Togashi, Minoru Suzuki, Toshiyoshi Fujiwara, Hiroyuki Michiue

Cancer Science 2024年8月

掲載種別：研究論文（学術雑誌）出版者・発行元：Wiley

Abstract

Immune checkpoint inhibitors (ICIs) are effective against many advanced malignancies. However, many patients are nonresponders to immunotherapy, and overcoming this resistance to treatment is important. Boron neutron capture therapy (BNCT) is a local chemoradiation therapy with the combination of boron drugs that accumulate selectively in cancer and the neutron irradiation of the cancer site. Here, we report the first boron neutron immunotherapy (B‐NIT), combining BNCT and ICI immunotherapy, which was performed on a radioresistant and immunotherapy‐resistant advanced‐stage B16F10 melanoma mouse model. The BNCT group showed localized tumor suppression, but the anti‐PD‐1 antibody immunotherapy group did not show tumor suppression. Only the B‐NIT group showed strong tumor growth inhibition at both BNCT‐treated and shielded distant sites. Intratumoral CD8+ T‐cell infiltration and serum high mobility group box 1 (HMGB1) levels were higher in the B‐NIT group. Analysis of CD8⁺ T cells in tumor‐infiltrating lymphocytes (TILs) showed that CD62L‐ CD44⁺ effector memory T cells and CD69⁺ early‐activated T cells were predominantly increased in the B‐NIT group. Administration of CD8‐depleting mAb to the B‐NIT group completely suppressed the augmented therapeutic effects. This indicated that B‐NIT has a potent immune‐induced abscopal effect, directly destroying tumors with BNCT, inducing antigen‐spreading effects, and protecting normal tissue. B‐NIT, immunotherapy combined with BNCT, is the first treatment to overcome immunotherapy resistance in malignant melanoma. In the future, as its therapeutic efficacy is demonstrated not only in melanoma but also in other immunotherapy‐resistant malignancies, B‐NIT can become a new treatment candidate for advanced‐stage cancers.

DOI： 10.1111/cas.16298

The effects of carbon-ion beam irradiation on three-dimensional in vitro models of normal oral mucosa and oral cancer: development of a novel tool to evaluate cancer therapy 査読

Eriko Naito, Kazuyo Igawa, Sho Takada, Kenta Haga, Witsanu Yortchan, Orakarn Suebsamarn, Ryota Kobayashi, Manabu Yamazaki, Jun-ichi Tanuma, Tsuyoshi Hamano, Takashi Shimokawa, Kei Tomihara, Kenji Izumi

In Vitro Cellular & Developmental Biology - Animal 2024年8月

Radiation evaluation assay using a human three-dimensional oral cancer model for clinical radiation therapy. 査読

Lucie Sercombe, Kazuyo Igawa, Kenji Izumi

Talanta Open 9 100297 - 100297 2024年8月

Hadron therapy in radiation oncology and why BNCT is a paradigm shift 査読

Wolfgang A. G. Sauerwein, Kazuyo Igawa, Joël Herault, Piero Fossati, Saverio Altieri, Raymond L. Moss, Andrea Wittig

Health and Technology 2024年5月

掲載種別：研究論文（学術雑誌）出版者・発行元：Springer Science and Business Media LLC

Abstract

Purpose

Hadrons, i.e. particles that are heavier than electrons, are playing an increasingly important role in radiation oncology. Due to the high investment costs for the necessary infrastructure, this option is only available in specialized centers.

Methods

This article describes some of the physical properties that make hadrons attractive for external beam radiation therapy (EBRT), but also some of the challenges that need to be considered.

Results

The importance of linear energy transfer for biological effects is discussed.

Conclusions

In addition to the use of charged particles, the importance of neutrons for radiotherapy is also highlighted, in particular the properties of boron neutron capture therapy (BNCT), which open up completely new possibilities for the further development of EBRT.

DOI： 10.1007/s12553-024-00848-5

その他リンク： https://link.springer.com/article/10.1007/s12553-024-00848-5/fulltext.html

The current status and novel advances of boron neutron capture therapy clinical trials. 査読国際誌

Tianyun Zhou, Kazuyo Igawa, Tomonari Kasai, Takuya Sadahira, Wei Wang, Tomofumi Watanabe, Kensuke Bekku, Satoshi Katayama, Takehiro Iwata, Tadashi Hanafusa, Abai Xu, Motoo Araki, Hiroyuki Michiue, Peng Huang

American journal of cancer research 14 ( 2 ) 429 - 447 2024年

記述言語：英語掲載種別：研究論文（学術雑誌）

Boron neutron capture therapy (BNCT) is a treatment method that focuses on improving the cure rate of patients with cancer who are difficult to treat using traditional clinical methods. By utilizing the high neutron absorption cross-section of boron, material rich in boron inside tumor cells can absorb neutrons and release high-energy ions, thereby destroying tumor cells. Owing to the short range of alpha particles, this method can precisely target tumor cells while minimizing the inflicted damage to the surrounding normal tissues, making it a potentially advantageous method for treating tumors. Globally, institutions have progressed in registered clinical trials of BNCT for multiple body parts. This review summarized the current achievements in registered clinical trials, Investigator-initiated clinical trials, aimed to integrate the latest clinical research literature on BNCT and to shed light on future study directions.

Development of the Follow-Up Human 3D Oral Cancer Model in Cancer Treatment 査読

Kazuyo Igawa, Kenji Izumi, Yoshinori Sakurai

BioTech 12 ( 2 ) 35 - 35 2023年5月

担当区分：筆頭著者,　責任著者掲載種別：研究論文（学術雑誌）出版者・発行元：MDPI AG

As function preservation cancer therapy, targeted radiation therapies have been developed for the quality of life of cancer patients. However, preclinical animal studies evaluating the safety and efficacy of targeted radiation therapy is challenging from the viewpoints of animal welfare and animal protection, as well as the management of animal in radiation-controlled areas under the regulations. We fabricated the human 3D oral cancer model that considers the time axis of the follow up in cancer treatment. Therefore, in this study, the 3D model with human oral cancer cells and normal oral fibroblasts was treated based on clinical protocol. After cancer treatment, the histological findings of the 3D oral cancer model indicated the clinical correlation between tumor response and surrounding normal tissue. This 3D model has potential as a tool for preclinical studies alternative to animal studies.

DOI： 10.3390/biotech12020035

Particle and Heavy Ion Transport Code System‐Based Microdosimetry for the Development of Boron Agents for Boron Neutron Capture Therapy 査読

Takafumi Shigehira, Tadashi Hanafusa, Kazuyo Igawa, Tomonari Kasai, Shuichi Furuya, Hisakazu Nishimori, Yoshinobu Maeda, Hiroyuki Michiue, Atsushi Fujimura

Advanced Theory and Simulations 2023年4月

Gelatin-based cell culture device for construction and X-ray irradiation of a three-dimensional oral cancer model. 査読国際誌

Tomoka Bessho, Tomoko Takagi, Kazuyo Igawa, Kae Sato

Analytical sciences : the international journal of the Japan Society for Analytical Chemistry 2023年2月

記述言語：英語掲載種別：研究論文（学術雑誌）

Bioassays using three-dimensional (3D) tissue models offer several advantages over 2D culture assays because they can reproduce the structure and function of native tissues. In this study, we used our newly designed gelatin device to generate a miniature 3D model of human oral squamous cell carcinoma with stroma and blood vessels. To enable air-liquid interface culture, we conceived a new device structure in which three wells were lined up and separated by a dividing thread; the wells could be connected by removing the dividing thread. Cells were seeded in the center well with the dividing thread to form a multilayer, followed by the supply of media from the side wells after thread removal. Human oral squamous cell carcinoma (HSC-4) cells, human umbilical vein endothelial cells (HUVECs), and normal human dermal fibroblasts (NHDFs) were successfully cocultured, resulting in structures that mimicked 3D-cancer tissues. This 3D-cancer model was subjected to an X-ray sensitivity assay, followed by the evaluation of DNA damage using confocal microscopy and section-scanning electron microscopy.

DOI： 10.1007/s44211-023-00308-6

正常口腔粘膜細胞と口腔癌細胞を用いた3次元in vitroモデル作製法とその応用

内藤絵里子, 小林亮太, 羽賀健太, 齊藤夕子, 山崎学, 田沼順一, 井川和代, 冨原圭, 泉健次

日本口腔科学会雑誌 71 ( 2 ) 61 - 61 2022年7月

Prevention and early management of carotid blowout syndrome for patients receiving head and neck salvage boron neutron capture therapy (BNCT). 査読国際誌

Tien-Li Lan, Feng-Chi Chang, Chun-Wei Wang, Kazuyo Igawa, Szu-Hsien Wu, Wen-Liang Lo, Yi-Wei Chen

Journal of dental sciences 16 ( 3 ) 854 - 860 2021年7月

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND/PURPOSE: The incidence rate of oral and pharyngeal cancers in Taiwan has increased gradually over the past few decades. The standard treatment strategy for oral and pharyngeal cancers includes surgery or radiotherapy, with concurrent chemotherapy in certain types of tumors. Unfortunately, in-field recurrence is sometimes inexorable. Furthermore, re-irradiation of the recurrence site may cause severe complications due to the tolerance of normal tissue to radiation therapy. One fatal complication is carotid blowout syndrome (CBS). Boron neutron capture therapy (BNCT) is a new modality of radiation therapy, which is also mentioned as targeted radiotherapy. It is a feasible treatment that has the potential to spare normal tissue from being damaged by irradiation while simultaneously treating the primary tumor. In this presentation, we will share our experience with BNCT in treating recurrent head and neck cancers, as well as the prevention and management of CBS. MATERIALS AND METHODS: We evaluated 4 patients with head and neck cancers treated by BNCT in Taiwan. All patients had undergone surgery previously and had received postoperative concurrent chemoradiotherapy. RESULTS: The 4 patients in this study were diagnosed with head and neck malignancies. The median follow-up period after the first course of BNCT was 15.1 months. After BNCT, 2 patients developed impending CBS, and 1 of them died. The remaining 3 patients survived until the last date of follow-up. CONCLUSION: Pre-BNCT carotid artery evaluation through computed tomography angiography and early intervention if necessary is crucial when treating patients with recurrent head and neck cancers by BNCT.

DOI： 10.1016/j.jds.2020.12.013

Self-assembling A6K peptide nanotubes as a mercaptoundecahydrododecaborate (BSH) delivery system for boron neutron capture therapy (BNCT). 査読国際誌

Hiroyuki Michiue, Mizuki Kitamatsu, Asami Fukunaga, Nobushige Tsuboi, Atsushi Fujimura, Hiroaki Matsushita, Kazuyo Igawa, Tomonari Kasai, Natsuko Kondo, Hideki Matsui, Shuichi Furuya

Journal of controlled release : official journal of the Controlled Release Society 330 788 - 796 2021年2月

記述言語：英語掲載種別：研究論文（学術雑誌）

Boron neutron capture therapy (BNCT) is a tumor selective therapy, the effectiveness of which depends on sufficient 10B delivery to and accumulation in tumors. In this study, we used self-assembling A6K peptide nanotubes as boron carriers and prepared new boron agents by simple mixing of A6K and BSH. BSH has been used to treat malignant glioma patients in clinical trials and its drug safety and availability have been confirmed; however, its contribution to BNCT efficacy is low. A6K nanotube delivery improved two major limitations of BSH, including absence of intracellular transduction and non-specific drug delivery to tumor tissue. Varying the A6K peptide and BSH mixture ratio produced materials with different morphologies-determined by electron microscopy-and intracellular transduction efficiencies. We investigated the A6K/BSH 1:10 mixture ratio and found high intracellular boron uptake with no toxicity. Microscopy observation showed intracellular localization of A6K/BSH in the perinuclear region and endosome in human glioma cells. The intracellular boron concentration using A6K/BSH was almost 10 times higher than that of BSH. The systematic administration of A6K/BSH via mouse tail vein showed tumor specific accumulation in a mouse brain tumor model with immunohistochemistry and pharmacokinetic study. Neutron irradiation of glioma cells treated with A6K/BSH showed the inhibition of cell proliferation in a colony formation assay. Boron delivery using A6K peptide provides a unique and simple strategy for next generation BNCT drugs.

DOI： 10.1016/j.jconrel.2020.11.001

Scaling parameter of the lethal effect of mammalian cells based on radiation-induced OH radicals: effectiveness of direct action in radiation therapy. 査読国際誌

Tamon Kusumoto, Ryo Ogawara, Kazuyo Igawa, Kentaro Baba, Teruaki Konishi, Yoshiya Furusawa, Satoshi Kodaira

Journal of radiation research 62 ( 1 ) 86 - 93 2021年1月

記述言語：英語掲載種別：研究論文（学術雑誌）

We have been studying the effectiveness of direct action, which induces clustered DNA damage leading to cell killing, relative to indirect action. Here a new criterion Direct Ation-Based Biological Effectiveness (DABBLE) is proposed to understand the contribution of direct action for cell killing induced by C ions. DABBLE is defined as the ratio of direct action to indirect action. To derive this ratio, we describe survival curves of mammalian cells as a function of the number of OH radicals produced 1 ps and 100 ns after irradiation, instead of the absorbed dose. By comparing values on the vertical axis of the survival curves at a certain number of OH radicals produced, we successfully discriminate the contribution of direct action induced by C ions from that of indirect action. DABBLE increases monotonically with increasing linear energy transfer (LET) up to 140 keV/μm and then drops, when the survival curves are described by the number of OH radicals 1 ps after irradiation. The trend of DABBLE is in agreement with that of relative biological effectiveness (RBE) of indirect action. In comparison, the value of DABBLE increases monotonically with LET, when the survival curves are described by the number of OH radicals 100 ns after irradiation. This finding implies that the effectiveness of C ion therapy for cancer depends on the contribution of direct action and we can follow the contribution of direct action over time in the chemical phase.

DOI： 10.1093/jrr/rraa111

The accelerator-based boron neutron capture reaction evaluation system for head and neck cancer. 査読国際誌

Shou Wang, Kazuyo Igawa, Ryo Ogawara, Mitsuru Suda, Tsuyoshi Hamano, Soichiro Ibaragi, Tadashi Hanafusa, Yasuaki Ichikawa, Akira Sasaki

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 165 109271 - 109271 2020年11月

担当区分：責任著者記述言語：英語掲載種別：研究論文（学術雑誌）

The purpose of this study is to assess accelerator-based boron neutron capture reaction (BNCR) in human tumor cell lines by colony formation assay and modified high density survival assay (HDS assay). The results of post irradiation survival rate in human oral squamous cell carcinoma and osteosarcoma using both assays were similar. Therefore, HDS assay would be efficient to evaluate BNCR in not only tumor cells but also in normal cells as BNCT screening.

DOI： 10.1016/j.apradiso.2020.109271

In Vitro Studies to Define the Cell-Surface and Intracellular Targets of Polyarginine-Conjugated Sodium Borocaptate as a Potential Delivery Agent for Boron Neutron Capture Therapy. 査読国際誌

Atsushi Fujimura, Seiji Yasui, Kazuyo Igawa, Ai Ueda, Kaori Watanabe, Tadashi Hanafusa, Yasuaki Ichikawa, Sachiko Yoshihashi, Kazuki Tsuchida, Atsunori Kamiya, Shuichi Furuya

Cells 9 ( 10 ) 2020年9月

記述言語：英語掲載種別：研究論文（学術雑誌）

Boron neutron capture therapy (BNCT) requires pharmaceutical innovations and molecular-based evidence of effectiveness to become a standard cancer therapeutic in the future. Recently, in Japan, 4-borono-L-phenylalanine (BPA) was approved as a boron agent for BNCT against head and neck (H&N) cancers. H&N cancer appears to be a suitable target for BPA-BNCT, because the expression levels of L-type amino acid transporter 1 (LAT1), one of the amino acid transporters responsible for BPA uptake, are elevated in most cases of H&N cancer. However, in other types of cancer including malignant brain tumors, LAT1 is not always highly expressed. To expand the possibility of BNCT for these cases, we previously developed poly-arginine peptide (polyR)-conjugated mercaptoundecahydrododecaborate (BSH). PolyR confers the cell membrane permeability and tumor selectivity of BSH. However, the molecular determinants for the properties are not fully understood. In this present study, we have identified the cluster of differentiation 44 (CD44) protein and translational machinery proteins as a major cell surface target and intracellular targets of BSH-polyR, respectively. CD44, also known as a stem cell-associated maker in various types of cancer, is required for the cellular uptake of polyR-conjugated molecules. We showed that BSH-polyR was predominantly delivered to a CD44High cell population of cancer cells. Once delivered, BSH-polyR interacted with the translational machinery components, including the initiation factors, termination factors, and poly(A)-biding protein (PABP). As a proof of principle, we performed BSH-polyR-based BNCT against glioma stem-like cells and revealed that BSH-polyR successfully induced BNCT-dependent cell death specifically in CD44High cells. Bioinformatics analysis indicated that BSH-polyR would be suitable for certain types of malignant tumors. Our results shed light on the biochemical properties of BSH-polyR, which may further contribute to the therapeutic optimization of BSH-BNCT in the future.

DOI： 10.3390/cells9102149

Clinical significance of buccal branches of the facial nerve and their relationship with the emergence of Stensen's duct: An anatomical study on adult Taiwanese cadavers. 査読国際誌

Chen-Hsi Tsai, Chun-Chan Ting, Szu-Yuan Wu, Jih-Yu Chiu, Hansheng Chen, Kazuyo Igawa, Ting-Hsun Lan, Chun-Ming Chen, Tsuoyoshi Takato, Kazuto Hoshi, Edward Chengchuan Ko

Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery 47 ( 11 ) 1809 - 1818 2019年11月

記述言語：英語掲載種別：研究論文（学術雑誌）

OBJECTIVE: This observational study on adult Taiwanese cadavers focused mainly on the intersection of buccal branches of the facial nerve with Stensen's duct, using the emergence of Stensen's duct as the reference landmark. MATERIALS AND METHODS: Thirty-five cadaveric hemifaces were included in our research. Samples with facial defects due to tumor, trauma, or surgery were all excluded. Buccal branches of the facial nerve were identified according to the Gray's Anatomy 40th edition definition. The distance was measured from the intersection to the emergence of Stensen's duct, running from the anterior border of the parotid gland. RESULTS: In the 35 hemifaces, the number of buccal branch/Stensen's duct intersections ranged from 1 to 5 (average 2.49 ± 1.15). Two-point intersections accounted for 37% (13 hemifaces) of the sample, forming the largest group. Samples of facial nerve buccal branches were divided into four types: Type 1, with two buccal branches, accounted for 37.15% (13/35); Type 2, with three buccal branches, made up 48.59% (17/35) of our samples - the biggest group (Type 2-a was the most frequent pattern among our samples, with two superior buccal branches and one inferior buccal branch, accounting for 34.31% of our samples); Type 3, with four buccal branches, accounted for only 5.7%. Three cases of double Stensen's duct were classified as Type 4, though this is supposed to be a very rare anatomical variation. With Type 2a, the most frequent pattern among our specimens, the distance from the emergence of the Stensen's duct to the emergence point of the first superior buccal branch along the anterior border of the parotid gland was 9.58 ± 5.68 mm. The distance from the emergence point to the emergence of the inferior buccal branch along the anterior border of the parotid gland was 11.03 ± 5.38 mm. The distance (D1) from Stensen's duct to the emergence of the first superiorly located buccal branch of the group Type 2-a was statistically different from the distance (D1) of the other groups (p = 0.02). No direct anastomoses or communicating fibers between upper and lower buccal branches were noted in 11 hemifaces (31%). CONCLUSION: The distribution of buccal branches was described using the emergence of Stensen's duct as a reference landmark. According to our observations, the relationship between the buccal branches and Stensen's duct was much more complicated than described in previous studies. This was the first study to investigate the complete distribution of buccal branches of the facial nerve emerging from the anterior of the parotid gland, and their relative locations and branching numbers.

DOI： 10.1016/j.jcms.2018.12.018

Development of thermal neutron moderator for testing boron agents for Boron Neutron Capture Therapy (BNCT) 査読

Ichikawa, G., Tsuchida, K., Kiyanagi, Y., Ishikawa, A., Hirata, Y., Yoshihashi, S., Watanabe, K., Uritani, A., Hamano, T., Ogawara, R., Suda, M., Igawa, K.

JOURNAL OF INSTRUMENTATION 14 2019年6月

担当区分：最終著者記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：IOP PUBLISHING LTD

We developed a thermal neutron source for performance tests of boron agents for Boron Neutron Capture Therapy (BNCT) at Neutron exposure Accelerator System for Biological Effect Experiments (NASBEE) in National Institute of Radiological Sciences, Japan. The thermal neutron flux at the experimental position was measured to be 2.18 x 10(8) n/cm(2)/s, the cadmium ratio was 9.21, and gamma ray dose ratewas 2.11 Gy/h. The neutron dose ratewas estimated to be 2.96 Gy/h. These values indicate that the neutron source can be applicable for tests of boron agents although application range is limited. An example of irradiation experiment is described.

DOI： 10.1088/1748-0221/14/06/T06010

上腕に発生した巨大悪性石灰化上皮腫の1例

井川和代, 北原正樹

日本形成外科学会会誌 37 ( 7 ) 393 - 398 2017年

記述言語：日本語出版者・発行元：(一社)日本形成外科学会

38歳男。20年前に右上腕部に皮下腫瘤が出現して徐々に増大し、1週間前より自壊、排膿してきた。右上腕部に約70×80mm大の易出血性、表面凹凸不整、石灰化様の硬結を伴う一部潰瘍化した腫瘤を認め、生検で石灰化上皮腫と診断した。手術を予定するも患者は来院せず、初診後4年に再診した際には腫瘤は約200×180mm大に巨大化し、有茎性、易出血性、非可動性の白色硬結が露出した不良肉芽様を呈していた。生検で悪性石灰化上皮腫と診断し、全身麻酔下に腫瘍頸部基部より5cm離して筋膜を含めて腫瘍を摘出し、欠損部を人工皮膚で被覆した。病理診断はpilomatrix carcinomaであった。術後1ヵ月に欠損部に対し大腿外側部からフリーハンドデルマトームを用いて中間分層皮膚を採取し、二期的に再建を行った。再建術から12ヵ月が経過し、再発は認めていない。

ホウ素中性子捕捉療法（BNCT)

井川和代, 瀬戸?一

クインテッセンス別冊 138 - 146 2015年

　前のページ - 次のページ　

1
2
3